- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04496037
Mechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant (MOT-AMR)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Design: Prospective observational study of patients enrolled in TAR:GET-1
Objectives: TAR-GET-1 (starting in 2019) is a multi-centre UK clinical trial that will compare standard of care (SOC) treatment of Acute Antibody-Mediated Rejection of the Kidney Transplant (AAMR) to standard of care plus rituximab (SOCR). This trial presents a rare opportunity to investigate the mechanisms of action of treatments (including rituximab) in AAMR. The rationale for using rituximab is the depletion of CD20-positive precursors to antibody-producing cells. However, rituximab has effects on other B cell subtypes and not all studies have shown antibody level reductions. Furthermore, AAMR is a heterogeneous disease, as defined by variability in mechanistic markers of AAMR in blood (B cell and antibody characteristics) and in transplant biopsies (histological features and gene expression).
The objectives of this study are:
- To investigate how treatment with rituximab affects these mechanistic markers, by comparing SOC to SOCR
- To predict treatment benefit early, by analysing the effect of treatment on the mechanistic markers
Methodology: In patients enrolled in TAR:GET-1 (n=170), mechanistic markers will be analysed with established proof of concept (B cell and antibody characteristics, histological and transcriptional markers in the biopsy) at baseline and on follow-up, making use of clinical data, surplus diagnostic material from TAR:GET-1, and material from optional extra blood samples for research taken as part of TAR:GET-1, at 3,6 and 12 months. An optional protocol biopsy at 6 months post treatment will also be offered.
TARGET-1 is assessing DSA MFI and target and B lymphocyte numbers at baseline and 3 months post-treatment. This study will in addition analyse:
- Serum DSA MFI and target at 6 months; complement-activating ability at baseline, 3 months and 6 months;
- Biopsy Banff histological scores at baseline and in post-treatment indication biopsies and an optional protocol biopsy;
- Biopsy AAMR-related transcript signature, assessed using Nanostring nCounter technology, at baseline and in post-treatment biopsies indication biopsies and an optional protocol biopsy;
- B lymphocyte numbers at 6 months.
Differences pre- and post-treatment will be analysed comparing SOC and SOCR. Mediation analysis models will be used to decompose total effect of treatment effect on graft loss at 4 years (primary end point) into an indirect effect, which measures how much of the effect acts through the intermediate variable(s), and a residual direct effect.
Number of Subjects and Study populations: 170 subjects enrolled in TAR:GET-1
Outcome measures: same as primary outcome of TAR:GET-1 (graft loss at 4 years after initiation of treatment)
Inclusion Criteria: All patients enrolled in TAR:GET-1 ; Signed informed consent prior to any study specific procedures.
Exclusion Criteria: None
Duration of study: 8 years (duration is dictated by the need for primary outcome of TAR-GET-1 to be reached)
Statistical Methods: Data from this research project will be merged and linked with data from the TAR:GET-1 clinical trial by the statistician team.
Descriptive data: This will include description of all the biological characteristics analysed in 2 populations (rituximab + SOC and SOC) at baseline and at all follow-up time points. Summary statistics (mean, median, SD, range for continuous variables, and frequency tables for categorical variables) will be reported broken down by treatment, with exploratory figures (box-and-whisker plots for continuous, and stacked bar-charts for categorical).
Outcome analysis: Appropriate measures of differences between treatment groups will be estimated with point estimates, 95% confidence intervals, and p-values. Depending on the type of variable (continuous, categorical, time-to-event), regression techniques (linear, logistic, cox) and transformation of the endpoints will be considered.
Differences in characteristics comparing pre- to post-treatment samples at sequential time points will be analysed comparing the 2 groups of patients (SOCR versus SOC) using r mixed effect models repeat measurement techniques.
Mediation analysis, a special case of regression analysis, will be used to document that the treatment effects a change in the biomarker. Mediation analysis models will be used to decompose total effect of treatment effect on graft loss into an indirect effect, which measures how much of the effect acts through the intermediate variable(s), and a residual direct effect. All the mediation analyses will be based on the Intention-to-Treat principle. The same form of outcome models will be fitted as for the efficacy analyses, including the mediator as a covariate. The mediation package within R will be used which was developed specifically to make valid causal inference in explanatory analyses of the mechanisms of treatment-induced change in clinical outcomes in randomised clinical trials. All estimates of treatment differences will be summarised using effect size estimates and 95% confidence intervals (Dunn 2013). Collaborator for mediation analysis: Prof Ian White, Professor of Statistical Methods for Medicine, UCL.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Candice Roufosse, MD PhD
- Phone Number: 02033138240
- Email: c.roufosse@imperial.ac.uk
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
All patients enrolled in TAR:GET-1 Signed informed consent prior to any study specific procedures.
Exclusion Criteria:
None
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Standard of care (SOC)
See NCT03994783
|
|
Rituximab + SOC (SOCR)
See NCT03994783
|
See NCT03994783
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Allograft Survival as assessed by statistical model
Time Frame: 4 years
|
Statistical model measuring allograft survival as defined as duration from the date of randomisation to the date of eGFR ≤15 mL/min/1.72
m2, or the date of renal replacement therapy (date of starting dialysis dependency, transplantation etc), whichever occurs first.
|
4 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Candice Roufosse, MD PhD, Imperial College London
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19HH5204
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Transplant; Complication, Rejection
-
Medical University of ViennaRecruitingTransplant; Complication, Rejection | Renal Transplant Rejection | Immune Repertoire | AlloreactivityAustria
-
Western Sydney Local Health DistrictNot yet recruitingKidney Transplant Rejection | Transplant Complication
-
Montefiore Medical CenterCareDxRecruitingTransplant; Complication, RejectionUnited States
-
University of MinnesotaCompletedKidney Transplant Rejection | Kidney Transplant; Complications | Transplant; Complication, Rejection | Kidney Transplant Failure and Rejection | Transplant DysfunctionUnited States
-
Fundación Pública Andaluza para la Investigación...Sociedad Andaluza de Trasplantes de Organos y TejidosCompletedRenal Transplant Rejection | Other Complication of Kidney TransplantSpain
-
Hopital FochRecruitingTransplant; Complication, RejectionFrance
-
Fondazione Policlinico Universitario Agostino Gemelli...UnknownLiver Transplant; Complications | Immunosuppression | Transplant; Complication, Rejection | Transplant FailureItaly
-
Rush University Medical CenterCareDxCompletedKidney Transplant Rejection | Pancreas Transplant RejectionUnited States
-
Stanford UniversityKaiser Foundation Research InstituteCompletedLung Transplant Rejection | Cardiac Transplant RejectionUnited States
-
Juan Francisco Delgado JimenezFundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIActive, not recruitingAntibody-mediated Rejection | Heart Transplant Rejection | Transplant FailureSpain
Clinical Trials on Rituximab
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingEBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)CompletedAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
PfizerCompletedRheumatoid ArthritisUnited States, Australia, Canada, Israel, Mexico, Colombia, Germany, Russian Federation, South Africa, United Kingdom
-
Mabion SAParexelWithdrawn
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaUnited States